Skip to main content
Fig. 1 | Experimental Hematology & Oncology

Fig. 1

From: Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML

Fig. 1

Clinical course of primary refractory AML patient with combination therapy with DNMT inhibitors, IDH inhibitors and Venetoclax: The patient was primary refractory after induction chemotherapy. The patient went into a complete remission (CR) after starting Azacytidine and Enasidenib. Venetoclax was added upon relapse and led to trilineage count recovery. Time periods are as follows: a Induction chemotherapy with Idarubicin and Cytarabine; b Salvage with Enasidenib and Decitabine; c Maintenance with Enasidenib and Azacytidine; d Relapse and brief treatment with Venetoclax; e Count Recovery; f Relapse

Back to article page

Experimental Hematology & Oncology

ISSN: 2162-3619

Contact us